On Two-Stage Hypothesis Testing Procedures Via Asymptotically Independent Statistics

James Dai
FHCRC, jdai@fhcrc.org

Charles Kooperberg
Fred Hutchinson Cancer Research Center, clk@fhcrc.org

Michael L. LeBlanc
Fred Hutchinson Cancer Research Center, mleblanc@fhcrc.org

Ross Prentice
University of Washington, rprentic@whi.org

Suggested Citation
http://biostats.bepress.com/uwbiostat/paper366

This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commercially reproduced without the permission of the copyright holder.
Copyright © 2011 by the authors
On two-stage hypothesis testing procedures via asymptotically independent statistics

James Y. Dai
1100 Fairview Ave N, M2-C200, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109
jdai@fhcrc.org

Charles Kooperberg
Fred Hutchinson Cancer Research Center, Seattle, WA, 98109

Michael LeBlanc
Fred Hutchinson Cancer Research Center, Seattle, WA, 98109

Ross L. Prentice
Fred Hutchinson Cancer Research Center, Seattle, WA, 98109

Summary. Kooperberg and LeBlanc (2008) proposed a two-stage testing procedure to screen for significant interactions in genome-wide association (GWA) studies by a soft threshold on marginal associations (MA), though its theoretical properties and generalization have not been elaborated. In this article, we discuss conditions that are required to achieve strong control of the Family-Wise Error Rate (FWER) by such procedures for low or high-dimensional hypothesis testing. We provide proof of asymptotic independence of marginal association statistics and interaction statistics in linear regression, logistic regression, and Cox proportional hazard models in a randomized clinical trial (RCT) with a rare event. In case-control studies nested within a RCT, a complementary criterion, namely deviation from baseline independence (DBI) in the case-control sample, is advocated as a screening tool for discovering significant interactions or main effects. Simulations and an application to a GWA study in Women’s Health Initiative (WHI) are presented to show utilities of the proposed two-stage testing procedures in pharmacogenetic studies.

Keywords: interactions; marginal effects; filtering; pharmacogenetics; randomization; case-only estimator.

1. Introduction

With the advent of high-throughput biotechnologies, e.g., microarray, Single Nucleotide Polymorphism (SNP) chips, and whole-genome sequencing, high-dimensional hypothesis testing has become a routine practice in exploratory biological or epidemiological studies. Statistical power in this setting has been limited by stringent significance rules, e.g., Bonferroni correction of multiple tests, that are required to guard against false positives arising from thousands or millions of tests. While investigators strive to ascertain a large number of biological samples, this is often constrained by cost and sample availability. Strategies on efficient design and analysis are therefore of critical importance.

In genome-wide association (GWA) studies, multi-stage designs have been employed in which all SNPs are screened first for suggestive evidence in a proportion of samples, and the most promising SNPs were tested in the next stage(s) (Satagopan et al., 2004; Prentice and Qi, 2006). Genotyping cost can be substantially reduced, yet with possibly little loss of power as compared to the
one-stage design, whether analysis is based on the replication data only (Satagopan et al., 2004), or combines data from multiple stages (Skol et al., 2006). Efficient analysis of genetic association data has also been extensively studied. Notable strategies encompass addressing local dependence of human genome by haplotype analysis (Lin and Zeng, 2006; Dai et al., 2009a), imputing unmeasured SNPs so that data from different platforms can be combined in meta-analysis (Li and Abecasis, 2006; Browning and Browning, 2007), and exploiting gene-environment independence assumption to gain efficiency (Chatterjee and Carroll, 2005; Dai et al., 2009b). Aside from the sheer number of tests, features of genetic inheritance of complex diseases pose additional threat to adequate power, e.g., multiple risk alleles, each having marginally weak associations, possibly interacting with other alleles or environmental attributes (Kraft, 2009).

When gene-gene or gene-environment interactions are targets of inference, there are ideas scattering in literature to filter out the majority of irrelevant SNPs upfront (Millstein et al., 2006; Kooperberg and LeBlanc, 2008; Murcray et al., 2008). The intuition is that, as long as the statistic used in the filtering stage is independent of the statistic in the testing stage, we only need to correct for the number of the tests actually passing the filtering, thus preserving power on features that are most promising. The filtering criterion was largely formulated by biological premises, e.g., SNPs with interactions are likely to have marginal effects (Kooperberg and LeBlanc, 2008), or gene-gene, gene-environment independence in a case-control sample should be expected if there is no interaction (Millstein et al., 2006; Murcray et al., 2008). Theoretical justification of these procedures, however, has not been elaborated.

In this article, we give a formal treatment of two-stage hypothesis testing procedures via independent statistics. We discuss in Section 2 the conditions that are required for such procedures to maintain strong control of family-wise error rate (FWER) in both high-dimensional and low-dimensional testing. Through use of estimating equation theory, we present in Section 3 a unified approach to prove the asymptotic independence of various statistics previously suggested. We discuss the utility of such procedures through examples in Section 3, that have a broader scope of hypothesis testing than just GWA studies. In Sections 4 and 5, we present simulations and data application to show the benefit of two-stage testing procedures.

2. A class of two-stage procedures and their strong control of FWER

Consider data from \( n \) subjects drawn from a cohort based on a prespecified sampling plan. Let \( Y_i \) denote the outcome variable, and let \( X_i = (X_{i1}, \ldots, X_{im}) \) denote a collection of \( m \) features measured for \( i^{th} \) subject. Occasionally, there is a low-dimensional variable of key interest, e.g., a randomized intervention, denoted by \( Z_i \). For different subjects, the random variables \((Y_i, X_i, Z_i)\) are independent and identically distributed. Let \( \theta_j, j = 1, \ldots, m \), denote the parameter of interest. The goal is to test \( m \) null hypotheses, \( H_{0j} : \theta_j = 0 \) versus \( H_{1j} : \theta_j \neq 0 \).

The test statistic for \( H_j \) is often formulated by asymptotically linear estimators (ALE) (Newey and Powell, 1990; Robins et al., 1994), scaled by its estimated standard error. An estimator \( \hat{\theta}_j \) of \( \theta_j \) is asymptotically linear if

\[
\sqrt{n}(\hat{\theta}_j - \theta_j) = 1/\sqrt{n} \sum_{i=1}^{n} B_{ij} + o_p(1), \quad E(B_j) = 0, \quad E(B_{ij}^2) < \infty.
\]

The function \( B_j \) is referred to as the influence function of \( \hat{\theta}_j \) in the sense of Casella and Berger (2002). By the Central Limit Theorem and Slutsky’s theorem \( \sqrt{n}(\hat{\theta}_j - \theta_j) \) is asymptotically normal with mean 0 and variance \( E(B_{ij}^2) \). Define a Wald test statistic

\[
T_j = \frac{\hat{\theta}_j}{\sqrt{\text{Var}(\hat{\theta}_j)}}.
\]

Now consider a different set hypothesis tests: \( K_{0j} : \theta_j = 0 \) versus \( K_{1j} : \theta_j \neq 0 \). Let \( \hat{\theta}_j \)

denote an asymptotically linear estimator of \( \theta_j \) as defined above. A Wald test statistic is formulated similarly,

\[
T_j^2 = \frac{\hat{\theta}_j}{\sqrt{\text{Var}(\hat{\theta}_j)}}.
\]
The following two-stage testing procedure is considered: denote by $\alpha_0$ a prespecified screening factor in the first stage, $0 < \alpha_0 < 1$. The corresponding first-stage critical region is $\Gamma_j^0 = \{ T_j^0 : |T_j^0| > C_j - \alpha_0/2 \}$, where $C_j - \alpha_0/2$ is the $1 - \alpha_0/2$ quantile of the standard normal distribution. Suppose there are $m_0$ features falling in the critical region. Let $0 < \alpha < 1$, and define the second-stage rejection region $\Gamma_j = \{ T_j^0 : |T_j^0| > C_j - \alpha/2 \alpha_0 \}$, where $C_j - \alpha/2 \alpha_0$ is the $1 - \alpha/2 \alpha_0$ quantile of the standard normal distribution. We declare a test statistically significant if $T_j^0 \in \Gamma_j^0$ and $T_j \in \Gamma_j$.

We show in the following theorems that with proper conditions, the two-stage testing procedure will control the FWER in the strong sense, though Bonferroni correction is only applied to the second-stage testing. Strong control of FWER means that for any set of null hypotheses, the probability of having at least one false positive test is less than or equal to the prespecified level $\alpha$ (Holm, 1979). The proof is given in the Appendix.

**Theorem 1.** If the asymptotic distribution of $\hat{\theta}_j$ and $\hat{\theta}_k$ are multivariate Gaussian, and they are uncorrelated, i.e.,

$$\text{Cov}\left(\sqrt{n}(\hat{\theta}_j - \theta_j), \sqrt{n}(\hat{\theta}_k - \theta_k)\right) \rightarrow_p 0 \quad \forall \quad j, k \in \{1, \ldots, m\}$$

the proposed two-step procedure preserves FWER at the level $\alpha$ asymptotically in the strong sense, i.e., for any non-empty index set $J \subseteq \{1, 2, \ldots, m\}$

$$\lim_{m \rightarrow \infty} \text{Pr}\left\{ \bigcup_{j \in J} (T_j^0 \in \Gamma_j^0 \cap T_j \in \Gamma_j) \mid H_{0,j}, K_{0,j} \right\} \leq \alpha.$$  

**Theorem 1** requires that the set of estimators in the first stage and the set of estimators in the second stage are jointly asymptotically independent, under the joint null hypothesis $H_{0,j}, K_{0,j}$. This is a rather restrictive condition. For mutually independent features $X_{ij}$, this condition reduces to uncorrelated $\hat{\theta}_j$ and $\hat{\theta}_j$. When $X_{ij}$ are correlated, we show in Section 3 that there are situations where two sets of estimators are jointly asymptotically independent, e.g., $H_j$ is on testing interactions of $X_{ij}$ with a randomized treatment assignment $Z_i$, and $K_j$ is on the marginal effect of $X_{ij}$.

**Theorem 1** applies regardless of the scale of hypothesis testing. When testing is high dimensional, the conditions can be relaxed as long as there is weak dependence among $X_{ij}$.

**Theorem 2.** In high-dimensional hypothesis testing, if the asymptotic distribution of $\hat{\theta}_j$ and $\hat{\theta}_j$ are multivariate Gaussian and they are uncorrelated, i.e.,

$$\text{Cov}\left(\sqrt{n}(\hat{\theta}_j - \theta_j), \sqrt{n}(\hat{\theta}_j - \theta_j)\right) \rightarrow_p 0 \quad \forall \quad j \in \{1, \ldots, m\},$$

and $\lim_{m \rightarrow \infty} \alpha_0$, the proposed two-step procedure preserves FWER at the level $\alpha$ for large $m$ and $n$ in the strong sense, i.e., for any non-empty index set $J \subseteq \{1, 2, \ldots, m\}$

$$\lim_{m \rightarrow \infty} \lim_{n \rightarrow \infty} \text{Pr}\left\{ \bigcup_{j \in J} (T_j^0 \in \Gamma_j^0 \cap T_j \in \Gamma_j) \mid H_{0,j}, K_{0,j} \right\} \leq \alpha.$$  

**Theorem 2** requires marginal asymptotic independence of $T_j^0$ and $T_j$ under the joint null hypothesis, which is satisfied for numerous examples in Section 3. The conditions required to obtain $\lim_{m \rightarrow \infty} \alpha_0$ are those required by the Law of Large Numbers (LLN) for correlated data. For instance, if

$$\text{Cov}\left( I(T_j^0 \in \Gamma_j^0 \mid H_{0,j}), I(T_k^0 \in \Gamma_k^0 \mid H_{0,k}) \right) \rightarrow 0,$$

when $|j - k|$ gets large, then the LLN for a sequence of $I(T_j^0 \in \Gamma_j^0 \mid H_{0,j})$ holds as $m \rightarrow \infty$ (White, 2001). This type of serial correlation is exactly the linkage disequilibrium pattern observed in human genome (The International HapMap Consortium, 2005).
Note that both theorems indicate strong control of FWER under the joint null hypotheses, \( H_{0j} \) and \( K_{0ij} \). The reason is that under the joint null, the test statistics \( T_j^0 \) and \( T_j \) are the centered z-scores \( \sqrt{n}(\hat{\theta}_j - \theta_j)/\sqrt{V_j}, \sqrt{n}(\hat{\theta}_k - \theta_k)/\sqrt{V_k} \) which are proved to be independent in the Appendix. Under the alternative hypothesis, our simulations suggest that \( T_j^0 \) and \( T_j \) are approximately independent as well (results not shown).

With minor modification, we can show that when a fixed top \( m_0 \) features, rather than a fixed rejection region, are selected for the second-stage testing, we still have strong control of FWER. Details are omitted. Certainly for such two-stage procedures to be useful, they should have more power than a Bonferroni correction for all features. One necessary requirement is that alternative rejection region, are selected for the second-stage testing, we still have strong control of FWER.

Moreover, the screening statistic \( E \) suitable regularity conditions (White, 1982) it can be shown that \( \sqrt{n}(\hat{\theta}_j - \theta_j) = \theta_j \), \( \sqrt{n}(\hat{\theta}_k - \theta_k) = \theta_k \). Let \( \hat{\theta} \) be the set of parameters in the model indexed by \( \theta \), and let \( \hat{\theta} \) denote the set of parameters in the model indexed by \( \theta \). Let \( \sum_{i=1}^n U_{1i} = 0 \) be the set of estimating equations solved for \( \theta \), and let \( \sum_{i=1}^n U_{2i} = 0 \) be the set of estimating equations to be solved for \( \hat{\theta} \). Suppose \( \theta \) is the unique solution to the estimating equations \( E[U_{1i}] = 0 \), where \( E \) denotes expectation under the true distribution. Similarly, \( \hat{\theta} \) is the unique solution to the estimating equations \( E[U_{2i}] = 0 \). Then \( \hat{\theta} \rightarrow_{a.s.} \theta \) and \( \hat{\theta} \rightarrow_{a.s.} \theta \).

Let \( A_1 = E[\partial U_{1i}/\partial \theta], A_2 = E[\partial U_{2i}/\partial \theta] \), and \( B_{kk'} = E[U_{ki}U_{k'i}] \), \( k, k' = 1, 2 \). With suitable regularity conditions (White, 1982) it can be shown that \( \sqrt{n}(\hat{\theta} - \theta) \) and \( \sqrt{n}(\hat{\theta} - \theta) \) are asymptotically equivalent to \( A_1^{-1}n^{-1/2}\sum_{i=1}^n U_{ki}, k = 1, 2 \). For each \( k \), the random vector \( U_{ki} \) is i.i.d with zero mean, but for the same \( i, U_{1i} \) and \( U_{2i} \) are possibly correlated. The joint distribution of \( \hat{\theta} \) and \( \theta \) is established by the Cramer-Wold device. Let \( t \) be a vector of 2 scalars, \( t_1 \) and \( t_2 \).

\[
\left( \sqrt{n}(\hat{\theta} - \theta) \right) = \left( \sqrt{n}(\hat{\theta} - \theta) \right) + o_p(1)
\]

\[
= t_1 A_1^{-1}n^{-1/2}\sum_{i=1}^n U_{1i} + t_2 A_2^{-1}n^{-1/2}\sum_{i=1}^n U_{2i} + o_p(1)
\]

\[
\rightarrow_d N(0, t_1^2 A_1^{-1}B_{11}A_1^{-1} + t_2^2 A_2^{-1}B_{22}A_2^{-1} + 2t_1 t_2 A_1^{-1}B_{12}A_2^{-1})
\]

This leads to the conclusion that the limiting distribution of \( \left( \sqrt{n}(\hat{\theta} - \theta), \sqrt{n}(\hat{\theta} - \theta) \right) \) is multivariate Gaussian with zero means and covariance matrix

\[
\begin{bmatrix}
A_1^{-1}B_{11}A_1^{-1} & A_1^{-1}B_{12}A_2^{-1} \\
A_2^{-1}B_{21}A_1^{-1} & A_2^{-1}B_{22}A_2^{-1}
\end{bmatrix}
\].

(1)
To assess asymptotic independence of $\hat{\varphi}$ and $\hat{\theta}$, we evaluate the off-diagonal element of their covariance matrix, $A_1^{-1}B_{12}A_2^{-1}$. This provides a unified approach to evaluate asymptotic independence among examples as followed. We first consider marginal independence between two estimators.

3.1. Marginal independence

**Example 1:** Consider a simple random sample with a continuous $Y$, e.g., a quantitative trait such as blood pressure, and a collection of high-dimensional features $X$. The interest is to identify pairwise interactions between two features, say $X_1$ and $X_2$, on $Y$ in an ordinary least square regression,

$$E[Y|X_1, X_2] = \gamma_0 + \gamma_1 X_1 + \gamma_2 X_2 + \gamma_3 X_1 X_2.$$  \hspace{1cm} (2)

There are $\binom{m}{2}$ pairwise interactions, which can be computationally infeasible to assess when $m$ is large. Kooperberg and LeBlanc (2008) suggests filtering out features without evidence of marginal association (MA) in a univariate regression,

$$E[Y|X_1] = \beta_0 + \beta_1 X_1.$$  \hspace{1cm} (3)

Let $X_1$ denote the design matrix of (2) with $n \times 4$ dimension, $(1, X_1, X_2, X_1 X_2)$. Let $X_2$ denote the design matrix of (3) with 2 columns, $(1, X_1)$. Let $Y$ denote the vector of the outcome variable, and $\hat{\beta} = (\beta_0, \beta_1), \gamma = (\gamma_0, \gamma_1, \gamma_2, \gamma_3)$. Since the OLS estimators $\hat{\beta}$ and $\hat{\gamma}$ have closed form,

$$\hat{\gamma} = (X_1^T X_1)^{-1} X_1^T Y,$$

$$\hat{\beta} = (X_2^T X_2)^{-1} X_2^T Y,$$

we can directly compute their covariance

$$\text{Cov}(\hat{\gamma}, \hat{\beta}) = (X_1^T X_1)^{-1} X_1^T X_2 (X_2^T X_2)^{-1}\hat{\sigma}^2,$$

where $\hat{\sigma}^2$ is the estimated residual variance under (2). Note that

$$(X_1^T X_1)^{-1} X_1^T X_2 = \begin{bmatrix} 1 & 0 \\ 0 & 1 \\ 0 & 0 \\ 0 & 0 \end{bmatrix},$$

because $(X_1^T X_1)^{-1} X_1^T X_1 = I$ and $X_2$ are contained in $X_1$. Hence

$$(X_1^T X_1)^{-1} X_1^T X_2 (X_2^T X_2)^{-1} = \begin{bmatrix} \cdots & \cdots & \cdots & \cdots \\ \cdots & \cdots & \cdots & \cdots \\ 0 & 0 & 0 & 0 \end{bmatrix}.$$

This implies that $\hat{\beta}_1$ and $\hat{\gamma}_3$ are uncorrelated, and hence independent for a normally distributed $Y$ at any sample size.

**Example 2a:** Consider a case-control study for a binary outcome $Y$. A collection of features $X$ were sampled retrospectively conditional on $Y$. The interest is to identify features that have pairwise interactions, similar to **Example 1**. The standard approach is to fit a logistic regression with interactions,

$$\logit\{E[Y|X_1, X_2]\} = \gamma_0 + \gamma_1 X_1 + \gamma_2 X_2 + \gamma_3 X_1 X_2.$$  \hspace{1cm} (4)
Similarly, Kooperberg and LeBlanc (2008) proposed to filter out features without much marginal association in a univariate logistic regression,

\[
\logit\{E[Y|X_1]\} = \beta_0 + \beta_1 X_1,
\]

though the proof was not shown explicitly.

Let \(\beta, \gamma, X_1, X_2\) be defined as in Example 1. Denote \(U_{1i}\) the score functions for (4) and \(U_{2i}\) the score functions for (5). Note that

\[
U_{1i} = X_{1i}(Y_i - E[Y_i|X_{1i}, X_{2i}]),
\]

\[
U_{2i} = X_{2i}(Y_i - E[Y_i|X_{1i}]).
\]

In case-control sampling, the likelihood is the retrospective distributions of covariates conditional on disease status. Remarkably, if a standard logistic regression is fitted to case-control data, \(\hat{\beta}_1\) and \(\hat{\gamma}_1, \hat{\gamma}_2, \hat{\gamma}_3\) are the semiparametric maximum likelihood estimators even though biased sampling is ignored (Prentice and Pyke, 1979). The score functions for regression coefficients from the profile likelihood are the same as \(U_{1i}\) and \(U_{2i}\) except for the intercepts.

We evaluate the terms in the covariance matrix (1). Observe that

\[
A_1 = E \left\{ (X_{1i}^T X_{1i})E[Y_i|X_{1i}](1 - E[Y_i|X_{1i}]) \right\},
\]

\[
B_{21} = E \left\{ (X_{1i}^T X_{2i}^T)(Y_i - E[Y_i|X_{1i}])(Y_i - E[Y_i|X_{2i}]) \right\},
\]

\[
A_2 = E \left\{ (X_{2i}^T X_{2i})E[Y_i|X_{2i}](1 - E[Y_i|X_{2i}]) \right\}.
\]

Thus by the Central Limit Theorem and Slutsky Theorem,

\[
A_1^{-1} B_{12} A_2^{-1} = n (X_1^T X_1)^{-1} (X_1^T X_2) (X_2^T X_2)^{-1} \left( \frac{1}{n} \sum_{i=1}^{n} \tilde{E}[Y_i|X_{1i}](1 - \tilde{E}[Y_i|X_{1i}]) \right) \left( \frac{1}{n} \sum_{i=1}^{n} (Y_i - \tilde{E}[Y_i|X_{1i}])(Y_i - \tilde{E}[Y_i|X_{2i}]) \right) \left( \frac{1}{n} \sum_{i=1}^{n} \tilde{E}[Y_i|X_{2i}](1 - \tilde{E}[Y_i|X_{2i}]) \right) + o_p(1).
\]

We have thus shown that

\[
(X_1^T X_1)^{-1} X_1^T X_2 (X_2^T X_2)^{-1} = \begin{bmatrix} \cdots & \cdots \\ \cdots & 0 \\ 0 & 0 \end{bmatrix}.
\]

Therefore the lower half submatrix of \(A_1^{-1} B_{12} A_2^{-1}\) is 0. This implies that \(\hat{\beta}_1\) and \(\hat{\gamma}_3\) are asymptotically uncorrelated, and thus asymptotically independent.

Example 2b: A variation of Example 2a is to replace the standard estimators of interactions in (4) by the so-called “case-only” estimators (Piegorsch et al., 1994; Umbach and Weinberg, 1997).
when the disease is rare and the two covariates, such as a gene and an environmental variable, are independent in the population. Despite the substantial efficiency gain, case-only estimators are generally sensitive to departures from gene-environment independence assumption (Albert et al., 2001). In genetic studies within randomized clinical trials (RCT), however, there exists indisputable independence between the treatment assignment and baseline covariates, including genetic variants. Henceforth, we focus on treatment-genotype interactions in a RCT.

Consider a randomized clinical trial with \( N \) subjects. Let \( Y_i \) denote the indicator variable of whether the \( i^{th} \) subject acquires a disease, \( i = 1, ..., N \). Assume that \( \Pr(Y_i = 1) \approx 0 \). Let \( Z_i \) denote the indicator variable of whether the treatment or the control assignment is received. Let \( \mathbf{X} = (X_1, ..., X_m) \) denote a collection of high-dimensional features, \( m \gg N \), e.g., SNPs in a whole-genome association study. If \( \mathbf{X} \) were to be measured for every participant, the joint density \( \{Y_i, Z_i, X_i\} \) is from i.i.d. random variables. However only a proportion of cases and a proportions of controls are sampled to collect \( \mathbf{X} \). We consider two logistic regressions: one regression consisting of \( Y \) on \( X_1 \) in cases and controls as in (5), the other consisting of \( Z \) on \( X_1 \) in cases only:

\[
\text{logit}\{\Pr[Z|X_1, Y=1]\} = \delta_0 + \delta_1 X_1. \tag{6}
\]

Following the same notations, for the \( i^{th} \) subject, the score functions can be expressed as followed:

\[
U_{i1} = \mathbf{X}_{i1}(Y_i - \E[Y_i|\mathbf{X}_{i1}]),
\]
\[
U_{i2} = \mathbf{X}_{i1}(Z_i - \E[Z_i|\mathbf{X}_{i1}, Y_i = 1])1_{[Y_i = 1]},
\]

where \( \mathbf{X}_{i1} \) is the design vector \((1, x_{1i})\). Note that \( U_{i2} = 0 \) if \( Y_i = 0 \). The covariance of \( \hat{\beta}_1 \) and \( \delta_1 \) can again be derived using estimating equation theory. Let \( \beta = (\beta_0, \beta_1) \) and \( \gamma = (\delta_0, \delta_1) \). Note that

\[
B_{21} = \E \left\{ \mathbf{X}_{i1} \mathbf{X}_{i1}^T (Y_i - \E[Y_i|\mathbf{X}_{i1}]) (Z_i - \E[Z_i|\mathbf{X}_{i1}, Y_i = 1]) 1_{[Y_i = 1]} \right\}
\]
\[
= \Pr(Y_i = 1) \E \left\{ \mathbf{X}_{i1} \mathbf{X}_{i1}^T (1 - \Pr[Y_i = 1|\mathbf{X}_{i1}]) (Z_i - \E[Z_i|\mathbf{X}_{i1}, Y_i = 1]) \right\}
\]
\[
= \Pr(Y_i = 1) \E_{\mathbf{X}_{i1}|Y=1} \left\{ \mathbf{X}_{i1} \mathbf{X}_{i1}^T (1 - \Pr[Y_i = 1|\mathbf{X}_{i1}]) \E_{Z_i|\mathbf{X}_{i1}, Y=1} (Z_i - \E[Z_i|\mathbf{X}_{i1}, Y_i = 1]) \right\}
\]
\[
= 0
\]

The second to the last equation use the law of iterated expectations. Hence the off-diagonal of the covariance matrix is zero and the proof is complete.

**Example 3:** So far we assume that features that have interactions should also manifest some main effects. Counterexamples can be constructed, e.g., two environmental groups with opposite signs of genetic effects. Another set of screening statistics can be developed to avoid this problem. In the rare-disease scenario considered in **Example 2b**, the association between \( Z \) and a feature, \( X_1 \) in the combined case-control sample may reveal some clues on interactions. Let

\[
\text{logit}\{\E[Z|X_1]\} = \tau_0 + \tau_1 X_1. \tag{7}
\]
\[
\text{logit}\{\E[Y|X_1, Z]\} = \gamma_0 + \gamma_1 X_1 + \gamma_2 Z + \gamma_3 X_1 Z. \tag{8}
\]

The rationale is as followed: when the disease is rare, we expect to have \( Z \perp X_1 \) in the controls. If there is interaction between \( Z \) and \( X_1 \), \( Z \) and \( X_1 \) are dependent in the cases. Due to oversampling of cases, \( Z \) and \( X_1 \) are dependent in the combined case-control sample. Thus we can select the top
features from the regression $Z \sim X_1$ for further interaction testing. This is somewhat similar to two-
step procedures previously proposed for gene-gene (Millstein et al., 2006) and gene-environment
interactions (Murcray et al., 2008), though confounding of the gene-gene or gene-environment in-
dependence is always an issue in observational studies. Intuitively, because we have not used the
disease information $Y$ to guide the screening, we do not have to spend type I error in screening. The
formal proof can be pursued similarly by estimating equation theory.

Following the notations in Example 2b, two sets of estimating equations are

$U_{11} = X_{1i}(Z_i - E[Z_i|X_{1i}]),$
$U_{12} = X_{1i}(Y_i - E[Y_i|X_{1i}, Z_i]),$

where $U_{11}$ is the score function of (7) and $U_{12}$ is the score function of (8).

$B_{21} = E\left\{X_{1i}X_{1i}^T(Z_i - E[Z_i|X_{1i}]) (Y_i - E[Y_i|X_{1i}, Z_i])\right\}$
$E_{Z,X}\left\{X_{1i}X_{1i}^T(Z_i - E[Z_i|X_{1i}]) E_{Y|Z,X}(Y_i - E[Y_i|X_{1i}, Z_i])\right\}$
$= 0.$

The derivation uses the law of iterated expectations, similar to that in Example 2b. Hence the
off-diagonal of the covariance matrix is zero and the proof is complete. Interestingly, asymptotic
independence does not hold when we use the case-only estimators for interactions in the second
stage. The reason might be that the information of rare diseases and the independence has been
used in formulating the first-stage estimator (7), therefore it cannot be used again in forming case-
only estimators.

Note that asymptotic independence also holds between $\gamma_1$ and $\gamma_2$. So it is possible to test for
main SNP effects in the control arm. Moreover, the same proof applies if (8) is replaced by any
regression model with $X_1$ and $Z$ as covariates, including

$\logit\{E[Y|X_1, Z]\} = \eta_0 + \eta_1 X_1 + \eta_2 Z.$

so that the adjusted effect of $X_1$ could be the test of interest after being filtered by $\gamma_1$ in (7). Since $Z$
is the randomized treatment assignment, the adjusted effect $\gamma_1$ approximates the marginal effect $\beta_1$
in (5). As $\gamma_1$ essentially assesses deviation from baseline independence (DBI) between $Z$ and $X_1$ in
the case-control sample, we call it the “DBI” criterion hereafter. These results suggest that in a RCT
with a rare outcome, we can use the criterion

$Pr(Y|Z, X) \neq Pr(Y|Z),$ i.e., there is a treatment effect conditional on $X$. Denote by $R$ the indicator of being
selected into the case-control sample. For a baseline predictor $X$, if we observe that

$Pr(Z|X, R = 1) \neq Pr(Z|R = 1),$

then

$Pr(Y|X, Z) \neq Pr(Y|Z).$
The proof is straightforward and left to Appendix. In Section 4, we compare the powers of two-stage procedures using MA and DBI under both rare-disease and common-disease scenarios.

**Example 4:** In RCTs, study endpoint is often time-to-event and primary inference is often based on the Cox proportional hazard model by partial likelihood. The score functions for partial likelihood take a specialized form and the arguments used to show independence in the previous examples do not apply. When the endpoint in an RCT is rare, however, we show below that the estimator for MA in a Cox model is asymptotically independent of a case-only estimator for interaction.

We switch to survival analysis notations for this example. Under the proportional hazard model, the hazard function for the failure time \( Y \) associated with covariates \((Z, X, Z X)\) is

\[
\lambda(y; Z, X) = \lambda_0(y) \exp(\beta_0 X + \beta_1 Z + \beta_2 Z X),
\]

where \( \beta_0 \) is the main effect of genotype \( X \), \( \beta_1 \) is the main effect of treatment \( Z \), \( \beta_2 \) is the interaction, and \( \lambda_0 \) is an unspecified baseline hazard function. When \( Y \) is subject to independent right-censorship, we observe \( T = \min(Y, C) \) and \( \Delta = I(Y \leq C) \), where \( C \) is the censoring time. Let \((T_i, \Delta_i, Z_i, X_i), i = 1, \ldots, n\) be \( n \) independent replicates. Then the partial likelihood function for \( \beta = (\beta_0, \beta_1, \beta_2) \) is

\[
L(\beta) = \prod_{i=1}^{n} \left( \frac{\exp(\beta' X_i)}{\sum_{j=1}^{n} R_j(T_i) \exp(\beta' X_j)} \right)^{\Delta_i},
\]

where \( X_i \) is the \( 3 \times 1 \) design vector, \( R_j(t) \) is the at-risk indicator \( I(T_j \geq t) \). The corresponding score function equals

\[
U(\beta) = \sum_{i=1}^{n} \Delta_i \left\{ X_i - \frac{S^{(1)}(\beta, X_i)}{S^{(0)}(\beta, X_i)} \right\},
\]

where \( S^{(0)}(\beta, t) = \sum_{j=1}^{n} R_j(t) \exp(\beta' X_j) \) and \( S^{(1)}(\beta, t) = \sum_{j=1}^{n} R_j(t) \exp(\beta' X_j) X_j \). If we fit a Cox model with only the marginal effect of \( X \), the model may be misspecified. Let \( \alpha \) denote the MA parameter in the Cox model. Under misspecified Cox models, the robust variance-covariance estimator for \( \hat{\alpha} \) is \( A^{-1}(\hat{\alpha})B(\hat{\alpha})A^{-1}(\hat{\alpha}) \) (Lin and Wei, 1989), where \( B(\alpha) = \sum_{i=1}^{n} W_i(\alpha)W_i(\alpha)' \).

\[
W_i(\alpha) = \Delta_i \left\{ X_i - \frac{S^{(1)}(\alpha, X_i)}{S^{(0)}(\alpha, X_i)} \right\} - \frac{\sum_{j=1}^{n} \Delta_j R_j(T_i) \exp(\alpha' X_j)}{nS^{(0)}(\alpha, X_j)} \left\{ X_j - \frac{S^{(1)}(\alpha, X_j)}{S^{(0)}(\alpha, X_j)} \right\},
\]

and

\[
A(\alpha) = \sum_{i=1}^{n} \Delta_i \left\{ \frac{S^{(2)}(\alpha, X_i)}{S^{(0)}(\alpha, X_i)} - \frac{S^{(1)}(\alpha, X_i)S^{(1)}(\alpha, X_i)'}{S^{(0)}(\alpha, X_i)^2} \right\}.
\]

Let \( s^{(r)}(\alpha, t) = E[S^{(r)}(\alpha, t)], r = 0, 1, N_i(t) = I(T_i \leq t, \Delta_i = 1), \bar{N}(t) = \sum_{i=1}^{n} N_i(t) \). Lin and Wei (1989) showed that \( n^{-1/2} \sum_{i=1}^{n} W_i(\alpha) \) is asymptotically equivalent to \( n^{-1/2} \sum_{i=1}^{n} w_i(\alpha) \),

\[
w_i(\alpha) = \int_{0}^{\infty} \left\{ X_i - \frac{s^{(1)}(\alpha, X_i)}{s^{(0)}(\alpha, X_i)} \right\} dN_i(t) - \int_{0}^{\infty} \frac{R_i(t) \exp(\alpha' X_i)}{s^{(0)}(\alpha, t)} \left\{ X_i - \frac{s^{(1)}(\alpha, t)}{s^{(0)}(\alpha, t)} \right\} d\bar{F}(t),
\]

where \( \bar{F}_n(t) = \bar{N}(t)/n \) and \( \bar{F}(t) = E[\bar{F}_n(t)] \).

Now suppose one wishes to assess and compare the treatment hazard ratios stratified by the genotype \( X = x \) valued at 0, 1, 2. The hazard rate at time \( T = t \) from randomization, may be specified as

\[
\lambda(t; Z, X) = \lambda_{0x} \exp(\beta_1 Z + \beta_2 Z X),
\]
so that \( \exp(\beta_1) \) is the treatment hazard ratio for subjects with \( x = 0 \), and \( \exp(\beta_2) \) indexes an additive interaction for subjects with \( x = 1, 2 \).

Observe that

\[
\frac{\Pr(Z = 1|T = t, X)}{\Pr(Z = 0|T = t, X)} = \frac{\Pr(T = t|Z = 1, X)\Pr(Z = 1|X)}{\Pr(T = t|Z = 0, X)\Pr(Z = 0|X)} = \frac{\Pr(T \geq t|Z = 1, X)\Pr(Z = 1|X)}{\Pr(T \geq t|Z = 0, X)\Pr(Z = 0|X)} \exp(\beta_1 Z + \beta_2 Z X)
\]

\[
= \frac{\Pr(Z = 1|T \geq t, X)}{\Pr(Z = 0|T \geq t, X)} \exp(\beta_1 Z + \beta_2 Z X).
\]

\( Z \) and \( X \) are independent by design, the event is rare and censoring rates are equal in two arms, it will follow that

\[
\frac{\Pr(Z = 1|T \geq t, X)}{\Pr(Z = 0|T \geq t, X)} = \frac{q}{1 - q}
\]

to an excellent approximation, where \( q \) is the fraction of the trial cohort assigned to the treatment. It follows that the \( \beta_1 \) and \( \beta_2 \) can be estimated using logistic regression of \( Z \) on \( X \) with \( \log(q/(1 - q)) \) as an “offset”. Though estimated by a logistic regression, these estimators have a hazard ratio interpretation in this context. Note that this version of case-only estimator allows for estimation of treatment hazard ratio in each subgroup, not just the interaction parameter in “standard” case-only estimators in logistic regression (Piegorsch et al., 1994). See Vittinghoff and Bauer (2006) for related work.

Let \( u_i(\beta) \) denote the estimating functions for this case-only estimator. Following the same argument we used in Example 2b, \( E[u_i(\beta)/u_i(\alpha)] = 0 \). Briefly, observe that \( u_i(\beta) \) is based on the distribution of \( Z|X, \Delta = 1 \) when \( \Delta = 1 \), and is zero otherwise. On the other hand, \( w_i \) is on the distribution of \( X|\Delta \). This leads to zero asymptotic covariance for \( \hat{\alpha} \) and \( \hat{\beta} \). We thus show that in RCT with a rare endpoint, the estimator of the marginal association in a Cox model is independent of the case-only estimator of the interaction. This result can be extended to Cox-model marginal association analyses based on such cohort sampling techniques as nested case-control and case-cohort sampling.

3.2. Joint independence

For two sets of asymptotically linear estimators, for instances \{\( \hat{\beta}_{1j}, j = 1, \ldots, m \} \) and \{\( \hat{\gamma}_{3k}, k = 1, \ldots, m \} \), joint independence implies that \( \hat{\beta}_{1j} \) and \( \hat{\gamma}_{3k} \) are uncorrelated \( \forall j, k \), since their joint distribution is multivariate Gaussian. This is a much stronger condition than no marginal correlation between \( \hat{\beta}_{1j} \) and \( \hat{\gamma}_{3j} \) for the same \( j \). In fact, pathological examples can be constructed to show that merely marginal independence in the two set of estimators could yield inflated FWER when \( m \) is small. In randomized clinical trials, however, joint independence can be achieved for estimators in Example 2a and 3 when the randomized assignment \( Z \) is involved, whether data are from the full cohort or a case-control sample. Next we show the proof for joint independence of \{\( \hat{\beta}_{1j}, j = 1, \ldots, m \} \) in (5) and \{\( \hat{\gamma}_{3k}, k = 1, \ldots, m \} \) in (8).

Let \( \bar{Z} \) denote the mean of \( Z_i \), and let \( \bar{X}_j \) denote the mean of \( X_{ij} \). We consider logistic regressions with centered versions of \( X_{ij} \) and \( Z_i \):

\[
\logit\{E[Y_i|X_{ik}]\} = \beta_{0k} + \beta_{1k}(X_{ik} - \bar{X}_k),
\]

\[
\logit\{E[Y_i|X_{ij}, Z_i]\} = \gamma_{0j} + \gamma_{1j}(X_{ij} - \bar{X}_j) + \gamma_{2j}(Z_i - \bar{Z}) + \gamma_{3j}(X_{ij} - \bar{X}_j)(Z_i - \bar{Z}).
\]
Again let $\beta_k = (\beta_{1k}, \beta_{2k})$ and $\gamma_j = (\gamma_{0j}, \gamma_{1j}, \gamma_{2j}, \gamma_{3j})$. Following the same notations in Example 2a, where $U_{1j}$ denote the score vector for $\gamma$, $U_{2j}$ denote the score vector for $\beta$. Denote by $V$ the covariance matrix of $\beta_k$ and $\gamma_j$. $V = A_1^{-1}B_{12}A_2^{-1}$. For $j \neq k$, not every element of $B_{21}$ is 0. However, it is easy to see that the lower half of this $4 \times 2$ matrix is 0. Denote by $B_{12,lv}$ the element of $B_{12}$ in the $l$th row and the $v$th column. Then

$$B_{12,31} = E\{(Z_i - \bar{Z})(Y_i - E[Y_i|X_{ij}, Z_i])(Y_i - E[Y_i|X_{ik}])\} = 0,$$

$$B_{12,41} = E\{(Z_i - \bar{Z})(X_{ij} - \bar{X}_j)(Y_i - E[Y_i|X_{ij}, Z_i])(Y_i - E[Y_i|X_{ik}])\} = 0,$$

$$B_{12,32} = E\{(Z_i - \bar{Z})(X_{ik} - \bar{X}_k)(Y_i - E[Y_i|X_{ij}, Z_i])(Y_i - E[Y_i|X_{ik}])\} = 0,$$

$$B_{12,42} = E\{(Z_i - \bar{Z})(X_{ik} - \bar{X}_k)(X_{ij} - \bar{X}_j)(Y_i - E[Y_i|X_{ij}, Z_i])(Y_i - E[Y_i|X_{ik}])\} = 0.$$

Similarly, we can show that the off-diagonal $2 \times 2$ submatrices of $A_1$ are 0. A little matrix algebra yields $V_{23} = V_{24} = 0$. Thus we proved the asymptotic independence of $\hat{\beta}_{1k}$ and $\hat{\gamma}_{3j}$, $\forall j \neq k$. We have shown previously the asymptotic independence of $\hat{\beta}_{1j}$ and $\hat{\gamma}_{3j}$. This leads to strong independence of $\{\hat{\beta}_{1j}, j = 1, ..., m\}$ and $\{\hat{\gamma}_{3k}, k = 1, ..., m\}$.

Note the same proof applies to the estimators in Example 3. As Theorem 1 stated, joint independence establishes strong control of FWER by a two-stage procedure, regardless the number of tests. As such, in a RCT where there are a number of baseline covariates, we could use both MA and DBI to screen for interactions between treatment- and baseline covariates.

3.3. A counterexample

We review a counterexample in which the independence of two statistics does not hold, so that an adaptive two-stage procedure would fail to preserve the type I error. This example pertains to choice of the estimator for a gene-environment interaction in an observational study. The case-only estimator is efficient, yet the required gene-environment independence is often subject to confounding. A naive adaptive procedure is to first test the independence of gene and environment factors in the controls, then use the case-only estimator or the standard interaction estimator when the first hypothesis is not rejected (Albert et al., 2001). Following the notations in Example 2b, let $Z$ denote the environmental factor and $X$ denote the genetic factor. We note that in the following three regression models,

$$\begin{align*}
\logit\{E[Z|X, Y = 0]\} &= \nu_0 + \nu_1X_1, \\
\logit\{E[Y|X, Z]\} &= \gamma_0 + \gamma_1X + \gamma_2Z + \gamma_3XZ, \\
\logit\{E[Z|X, Y = 1]\} &= \delta_0 + \delta_1X.
\end{align*}$$

$\hat{\nu}_1$ is independent of $\delta_1$ since they use different data, yet $\hat{\nu}_1$ is not independent of $\gamma_3$. So using $\hat{\nu}_1$ to decide whether to use $\hat{\gamma}_3$ or $\hat{\delta}_1$ will incur an inflated type I error (Albert et al., 2001).

4. Simulations

We first examine empirical correlations of various pairs of statistics in small samples by simulation. We generated 20,000 simulated datasets from the logistic regression model (4), in which parameters are $\gamma = (-1, 0, 0, \gamma_3)$ with varying levels of interactions $\gamma_3 = 0, 0.5, \text{or } 1$. The sample sizes of the simulated datasets were 200, 1000, and 5000. $X_1$ and $X_2$ were generated as bivariate normal
distribution with means 0 and variances 1. We introduced a range of correlation between $X_1$ and $X_2$ from 0 to 0.8. Table 1 shows the empirical correlation of $\beta_1$ and $\gamma_3$, and empirical correlation of their corresponding centered $z$-scores in various parameter settings. The centered $z$-score is the centered estimator (estimator subtracted by the mean), scaled by the sandwich variance estimator. Clearly even with a sample size of 200, the asymptotic independence holds fairly well across different levels of interactions and different levels of covariate correlations.

We also simulated case-control samples that are nested within a randomized clinical trial (Example 2b and 3). A binary randomized treatment variable was generated from $Ber(0.5)$, the SNP has minor allele frequency 0.2 and diploids were formed assuming the Hardy-Weinberg equilibrium. The logistic regression model (4) with $\gamma = (-4.5, 0, 0, \gamma_3)$ was used to generate the disease data for $N = 2 \times 10^4, 10^5, 5 \times 10^5$. The marginal disease probability is around 0.01. Again we varied the size of interaction at 0, 0.5 and 1. The sizes of the second-stage case-control samples are approximately 400, 2000, 10000, with a 1:1 case-control ratio. Table 2 shows the empirical correlations of various statistics in 20,000 simulated datasets. With sample size 400 and beyond, the correlation of various pairs of statistics is fairly close to zero as theory predicts. The pair of statistics in the counterexample display a consistent correlation around $-0.7$, confirming that using such statistics in an adaptive testing procedure would yield an inflated type I error.

In Table 3, we assess the empirical FWER over 1000 simulated datasets, each containing 10,000 SNPs for 1000 subjects. The minor allele frequencies were randomly generated from a uniform distribution from 0.1 to 0.5. The SNPs are either independent ($\rho = 0.5$) or have a serial correlation ($\rho = 0.5$). A binary treatment assignment was randomly generated by $Ber(0.5)$. The binary disease status was generated by the logistic model (8) with $\gamma = (-4, 0, 0, 0)$ or $(-4, 0, \log(1.5), 0)$, the latter assumes a mild treatment effect. Various two-stage procedures in Example 2a, 2b and 3 were applied to screen for main effects or interactions with $\gamma_0 = 0.001, 0.01$, or 0.1, and $\alpha = 0.05$. For each pair of statistics, we alternated the screening statistics and the testing statistics. For example, we could use interactions as screening criteria for testing main effects. Across all settings, FWERs are controlled at the level of 0.05; as expected, none of them falls outside of 95% confidence intervals of 0.05.

We study in Figure 1 and Figure 2 the power performance for the procedures in simulations with half a million independent SNPs, one of which is true alternative hypothesis and the rest are all nulls. The SNPs were generated based on Hardy-Weinberg equilibrium. The simulation was designed with a case-control study nested in a randomized clinical trial (Example 2b and 3). The
Table 2. The empirical correlations of various statistics in Example 2a-3 with case-control sampling among 20,000 simulated case-control data. The parameters are from the following models: $\beta_1$: $\logit\{E[Y|X]\} = \beta_0 + \beta_1 X$; $\gamma_3$: $\logit\{E[Y|X,Z]\} = \gamma_0 + \gamma_1 X + \gamma_2 Z + \gamma_3 XZ$; $\delta_1$: $\logit\{E[Z|X,Y = 1]\} = \delta_0 + \delta_1 X$; $\tau_1$: $\logit\{E[Z|X]\} = \tau_0 + \tau_1 X$; $\nu_1$: $\logit\{E[Z|X,Y = 0]\} = \nu_0 + \nu_1 X$.

<table>
<thead>
<tr>
<th>$\gamma_3 = 0$</th>
<th>$\beta_1 : \gamma_3$</th>
<th>$\beta_1 : \delta_1$</th>
<th>$\gamma_1 : \gamma_3$</th>
<th>$\gamma_1 : \delta_1$</th>
<th>$\nu_1 : \gamma_3$</th>
<th>$\nu_1 : \delta_1$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$-0.004$</td>
<td>$-0.004$</td>
<td>$-0.001$</td>
<td>$-0.004$</td>
<td>$-0.702$</td>
<td>$-0.708$</td>
</tr>
<tr>
<td>$n = 400$</td>
<td>$0.002$</td>
<td>$0.001$</td>
<td>$0.003$</td>
<td>$0.001$</td>
<td>$-0.703$</td>
<td>$-0.709$</td>
</tr>
<tr>
<td>$n = 2000$</td>
<td>$0.003$</td>
<td>$-0.004$</td>
<td>$0.003$</td>
<td>$0.001$</td>
<td>$-0.706$</td>
<td>$-0.709$</td>
</tr>
<tr>
<td>$n = 10000$</td>
<td>$0.003$</td>
<td>$-0.004$</td>
<td>$0.003$</td>
<td>$0.001$</td>
<td>$-0.706$</td>
<td>$-0.709$</td>
</tr>
</tbody>
</table>

Table 3. The empirical FWER in 1000 simulations. 10,000 SNPs are simulated for 1000 cases and 1000 controls by case-control sampling. SNPs are generated either independently or with serial correlation 0.5. The disease status is generated by the logistic model (8). The parameters are from the following models: $\beta_1$: $\logit\{E[Y|X]\} = \beta_0 + \beta_1 X$; $\gamma_3$: $\logit\{E[Y|X,Z]\} = \gamma_0 + \gamma_1 X + \gamma_2 Z + \gamma_3 XZ$; $\delta_1$: $\logit\{E[Z|X,Y = 1]\} = \delta_0 + \delta_1 X$; $\tau_1$: $\logit\{E[Z|X]\} = \tau_0 + \tau_1 X$. $\beta_1 \rightarrow \gamma_3$ indicates using $\beta_1$ for screening, and $\gamma_3$ for testing.

<table>
<thead>
<tr>
<th>$\rho$ = 0 $\beta_1$</th>
<th>$\gamma_3$</th>
<th>$\delta_1$</th>
<th>$\alpha_1$</th>
<th>$\rho$ = 0.5 $\beta_1$</th>
<th>$\gamma_3$</th>
<th>$\delta_1$</th>
<th>$\alpha_1$</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\alpha_0 = 0.001$</td>
<td>$0.037$</td>
<td>$0.043$</td>
<td>$0.042$</td>
<td>$\alpha_0 = 0.001$</td>
<td>$0.044$</td>
<td>$0.046$</td>
<td>$0.042$</td>
</tr>
<tr>
<td>$\alpha_0 = 0.01$</td>
<td>$0.050$</td>
<td>$0.048$</td>
<td>$0.041$</td>
<td>$\alpha_0 = 0.01$</td>
<td>$0.053$</td>
<td>$0.040$</td>
<td>$0.042$</td>
</tr>
<tr>
<td>$\alpha_0 = 0.1$</td>
<td>$0.050$</td>
<td>$0.045$</td>
<td>$0.041$</td>
<td>$\alpha_0 = 0.1$</td>
<td>$0.053$</td>
<td>$0.040$</td>
<td>$0.042$</td>
</tr>
</tbody>
</table>

$\gamma = (-4, 0, 0, 0)$ $\gamma = (-4, 0, \log(1.5), 0)$
Fig. 1. Power to detect the treatment-SNP interaction using two-stage procedures in simulations. Assuming one of 1 million SNPs carries disease risk, the risk model takes form of \( \logit\{E[Y|X,Z]\} = \gamma_0 + \gamma_1 X + \gamma_2 Z + \gamma_3 XZ \). The parameters are from the following models: MA - \( \beta_1 \), \( \logit\{E[Y|X]\} = \beta_0 + \beta_1 X \); Standard Interaction - \( \gamma_3 \), \( \logit\{E[Y|X,Z]\} = \gamma_0 + \gamma_1 X + \gamma_2 Z + \gamma_3 XZ \); CaseOnly - \( \delta_1 \), \( \logit\{E[Z|X,Y = 1]\} = \delta_0 + \delta_1 X \); DBI - \( \tau_1 \), \( \logit\{E[Z|X]\} = \tau_0 + \tau_1 X \).
Fig. 2. Power to detect the SNP main effect using two-stage procedures in simulations. Assuming one of 1 million SNPs carries disease risk, the risk model takes form of logit{E[Y|X, Z]} = γ₀ + γ₁X + γ₂Z + γ₃XZ. The parameters are from the following models: MA - β₁, logit{E[Y|X]} = β₀ + β₁X; γ₃, Standard Interaction - logit{E[Y|X, Z]} = γ₀ + γ₁X + γ₂Z + γ₃XZ; Case-Only - δ₁, logit{E[Z|X, Y = 1]} = δ₀ + δ₁X; DBI - τ₁, logit{E[Z|X]} = τ₀ + τ₁X; Adjusted MA - η₁, logit{E[Y|X, Z]} = η₀ + η₁X + η₂Z
randomization ratio to the treatment arm and the control arm is 1:1, and the case-control sampling ratio is also 1:1. The power was computed as the percentage of simulations where the SNP with the signal was declared to be significant in 10,000 simulations. With almost half a million null tests, the number of tests passing the first stage criterion would vary little from $n_{a0}$, so we used the second stage cut-off $C_{1-\alpha/(2m_{a0})}$ as if it was fixed in every simulation. We devised various parameter settings and a range of $\alpha_0$ to study the full spectrum of operating characteristics.

Figure 1 shows the power to detect an interaction between the signal SNP ($X$) and the treatment $Z$. Denote by $N$ the total sample size, $n$ the sample size for the case-control sample, $p$ is the minor allele frequency of the target SNP, $\gamma$ is the vector of parameters in the model (8) that generates the data. Across 4 graphs, the red curve is the power of screening main effects by $\hat{\beta}_1$ before testing interactions using the case-only estimator ($\hat{\delta}_1$), for $\alpha_0$ valued from 0.00001 to 0.1; the black curve is the power of screening by main effects $\hat{\beta}_1$ before testing interactions using the standard estimator ($\hat{\gamma}_3$); the green line is the power of screening by DBI $\hat{\tau}_1$ before testing interaction ($\hat{\gamma}_3$). The red horizontal dotted line is the power of testing for case-only interactions by Bonferroni correction for half a million test; the black horizontal dotted line is the power of testing for standard interactions by Bonferroni correction for half a million tests. These two dotted lines provide benchmarks for a comparison of power.

In Figure 1(a), $N = 50,000, n \approx 1000, p = 0.1, \gamma = (-4, 0, 0, \log 2)$. The marginal disease probability is around 0.02. Clearly, the case-only estimator provides a substantial lift of power on top of the standard interaction estimator. The two-stage procedure with MA and case-only estimator yields substantial power improvement over other procedures. The two-stage procedure with DBI and standard interaction estimators is slightly outperformed by first screening main effects. In Figure 1(b), $N = 50,000, n \approx 1000, p = 0.2, \gamma = (-4, -0.5 \log 2, 0, \log 2)$, so that the interaction between the treatment and the SNP is qualitative, i.e., the sign of the SNP effect differs in different treatment groups. The main effect of the SNP is negligible, which lead to poor power performance of the two-stage procedures using main effects for an initial screen. The two-stage procedure using DBI avoids the cancellation of opposite SNP effects, thus yields a noticeable power gain over the two-stage procedures using main effects. The best procedure in this scenario is, however, the case-only estimator with Bonferroni correction (the dotted red line), suggesting that in rare disease settings, case-only estimators are preferable wherever possible. We show in Example 3 that DBI can be extended to settings with common diseases, as long as there is a treatment effect. In Figure 1(c), $N = 50,000, n \approx 1000, p = 0.2, \gamma = (-2, 0, -\log 1.5, \log 2)$. The disease probability is roughly 10% and there is a mild treatment effect and a strong interaction effect. Case-only estimators are no longer eligible, yet the two-stage procedure using MA to filter still performs better than the two-stage procedure using DBI, both improving upon the standard interactions. In Figure 1(d), $N = 50,000, n \approx 1000, p = 0.3, \gamma = (-2, -\log 1.8, \log 1.5, \log 2)$. There is a qualitative interaction and thus a small marginal SNP effect, hence the two-stage procedure using MA to screen has little power to detect the true interaction, while screening by DBI in this scenario yields much better power.

Figure 2 shows the power to detect the SNP effect using two-stage procedures either using interaction or DBI as the screening criterion. The labels for various procedures are similar to those in Figure 1, except that the SNP effect, either marginal or adjusted for treatment, is of interest after screening. In Figure 2(a), $N = 50,000, n \approx 1000, p = 0.1, \gamma = (-4, \log 1.5, 0, \log 1.5)$. Clearly in this setting, the best procedure is to test the marginal effect directly, two-stage procedures using either interaction or DBI in screening does not perform comparably. The reason is that testing for interaction, even with case-only estimator, is more costly to sample size than testing for main effect, therefore screening by interactions for marginal effects does not help when there is a moderate size of interaction. In Figure 2(b), $N = 50,000, n \approx 1000, p = 0.1, \gamma = (-4, -\log 1.8, \log 0.8, \log 2)$.
Since the marginal SNP effect is small and the interaction is fairly big, using interaction or DBI to find marginal effect yields much better power than one-stage Bonferroni correction for MA or adjusted MA.

Taking collectively, each of the proposed two-stage procedures has unique niche in power performance. There are situations where none of them improves power upon the one-stage all-SNP Bonferroni test, see Figure 1(b) and Figure 2(a). It is useful to screening by MA for interactions, since testing main effect is generally more powerful than testing interaction, so that a SNP having interaction is likely to have high probability to pass the filter. However when there are qualitative interactions, which might be not common, the two-stage procedure using MA does not perform well since the marginal effect is small. The DBI criterion offers an alternative screening procedure which can improve power in this setting, see Figure 1d. It appears less useful to screen for marginal effects by interactions or DBI, unless there are qualitative interactions (Figure 2(b)). In any case the marginal effect is usually of primary interest, so we may well have good power to test all SNPs.

4.1. optimal $\alpha_0$

Clearly in Figure 1 and 2, an optimal $\alpha$ can be achieved, since more tests passing the first stage will incur more penalty by Bonferroni correction. For simulations with half a million SNPs in Figure 1 and 2, the optimal $\alpha_0$ for power performance is fairly small, in the range of $0.0001 \sim 0.001$. Analytically, it is possible to find the optimal $\alpha_0$ for a hypothesized disease risk model and a sampling plan, since power to detect a feature can be written out approximately,

$$\Pr(T_0^j \in \Gamma_0^j, T_j \in \Gamma_j | H_{1j}) \approx \Pr(T_0^j > C_{1-\alpha_0/2} | H_{1j}) \Pr(T_j > C_{1-\alpha/(2m_{\alpha_0})} | H_{1j}).$$

With prior assumptions on an alternative hypothesis, the asymptotic distribution of $T_0^j$ and $T_j$ under $H_{1j}$ can be derived for a fixed sample size, so that an optimal $\alpha_0$ can be computed. Alternatively, power simulations can be conducted using our R-package powerGWASinteraction from CRAN to obtain the optimal $\alpha_0$. In any case, it is important to note that we need to set $\alpha_0$ fixed before performing hypothesis testing. Data-adaptive selection of $\alpha_0$ will undermine error control.

5. Data application

The Women’s Health Initiative (WHI), one of the largest studies of postmenopausal women’s health in the U.S., is composed of four randomized clinical trials (CT) and an observational study (OS). An elevated invasive breast cancer risk was found among women assigned to estrogen plus progestin, with suggestive evidence of risk reduction among women assigned either to estrogen-alone or to a low-fat dietary pattern. To discover the genetic variants that may influence the risk, perhaps jointly with the interventions, WHI launched a genome-wide association study with a three stage design (Prentice and Qi, 2006). In the third stage, a total of 9039 SNPs were selected from previous stages or other studies, and were genotyped among 2,166 invasive breast cancer cases in the CT and 1:1 matched controls. Primary analyses have been presented recently (Prentice et al., 2009, 2010). Seven SNPs in the fibroblast growth factor receptor 2 (FGFR2) met criteria for genome-wide significance. Recognizing limited power in detecting interactions, the investigators focused the search for treatment-genotype interactions to the top seven SNPs ranked by MA (Prentice et al., 2009, 2010), as well as a number of SNPs that have been reported in the literature to be associated with breast cancer (Huang et al., 2010). Since invasive breast cancer is a rare event in the study, the investigators used the case-only estimators described in Example 4. A number of SNPs showed suggestive evidence of interactions with one or more interventions. The analyses presented here are exploratory and supplementary to the findings from these primary analyses.
Table 4. The results of two-stage procedures applied to the WHI GWAS, using DBI as a screening criterion. Four SNPs out of the top 50 SNPs ranked by the DBI criterion reach statistical significance in testing the adjusted marginal SNP effect.

<table>
<thead>
<tr>
<th>SNP</th>
<th>E-alone</th>
<th>All trials</th>
<th>OR</th>
<th>p-value</th>
<th>OR</th>
<th>p-value</th>
<th>OR</th>
<th>p-value</th>
<th>OR</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs7705343</td>
<td>(\hat{\alpha}_1)</td>
<td>1.5823</td>
<td>0.0006</td>
<td>1.5217</td>
<td>0.0014</td>
<td>1.4701</td>
<td>0.0035</td>
<td>1.4269</td>
<td>0.0063</td>
<td></td>
</tr>
<tr>
<td>rs13159598</td>
<td>(\hat{\eta}_1)</td>
<td>1.1672</td>
<td>0.0006</td>
<td>1.1653</td>
<td>0.0007</td>
<td>1.1649</td>
<td>0.0007</td>
<td>1.1695</td>
<td>0.0005</td>
<td></td>
</tr>
<tr>
<td>rs9790879</td>
<td>(\hat{\delta}_1)</td>
<td>1.5231</td>
<td>0.0298</td>
<td>1.4657</td>
<td>0.0444</td>
<td>1.3842</td>
<td>0.0907</td>
<td>1.3832</td>
<td>0.0936</td>
<td></td>
</tr>
<tr>
<td>rs4415084</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Our results justified the focused search for interactions in a subset of SNPs ranked by top marginal association. In addition, we also explored the two-stage procedures using the DBI criterion to look for significant marginal effects and interactions (Example 3). This is done separately for each of the 4 randomized trials. In the first stage, we ranked SNPs by p-values for DBI. We tested for main effects and interactions for the top 50 SNPs ranked by DBI. Among the top 50 SNPs ranked by DBI in the E-alone trial, there are four SNPs that pass the Bonferroni correction for 50 SNPs in testing for adjusted SNP effect. Table 3 shows the parameter estimates of these 4 SNPs. The adjusted additive SNP effect \(\hat{\eta}_1\) was estimated from case-control data for all 4 trials, adjusted for matching variables, important baseline predictors and randomization indicators. The effect size (odds ratio) is fairly modest around 1.16. In the E-alone trial, there seems to be a weak interaction between the SNPs and the treatment. The effect sizes of the interactions (case-only estimator \(\hat{\delta}_1\)) are around 1.4 - 1.5.

Interestingly, these four SNPs are all located in the MRPS30 gene which have been shown to have suggestive evidence of interaction with multiple clinical interventions (Huang et al., 2010), though the findings there are guided by prior studies. None of them would reach the genome-wide significance level for either marginal effect or interaction, yet they reach the FWER level of 0.05 for marginal association by our two-stage procedure. The reason might be that these four SNPs have weak main effects and weak interactions with the E-alone intervention. The DBI criteria seem to synthesize these weak effects and prioritizes them for further testing. This data example suggests that two-stage procedures can be used as data-adaptive tool, as opposed to candidate genes from prior studies, for discovering novel genes affecting disease risk. Certainly this search strategy only serves as a supplement to the standard one-stage Bonferroni test, since it missed the seven SNPs in the FGFR2 gene.

6. Discussion

We studied conditions that are required to maintain strong control of FWER for a class of two-stage hypothesis testing procedures previously proposed. We provided a unified approach to prove asymptotic independence by estimating equation theory. Two types of screening statistics are discussed, one is based on marginal association (MA) and the other is based on deviation from baseline independence (DBI). In the majority of simulation settings, one or both of the proposed procedures outperform the standard one-stage testing with Bonferroni correction.

The impact of these results is profound to discovering baseline features that influence treatment effect in a RCT, whether they are low or high-dimensional. In randomized clinical trials, subgroup analyses are heavily criticized as having low power to detect interactions in general, which could be further exacerbated by data-adaptive procedures. Our results suggest that one could select predictors with evidence of MA or with evidence of DBI to test for interactions, without spending type I error in finding these candidate predictors. We expect that the two-stage procedures will be most
useful to discovering interaction in pharmacogenetic studies, where it is almost certain that these studies have low power to detect interactions. In fact, we are involved in a GWAS study within the WHI clinical trials as part of the Genomics and Randomized Trials Network (GARNET) program (www.garnetstudy.org) in which we plan to use this strategy. Using interactions or DBI to screen for marginal effect appears less powerful in general, at most serving as exploratory supplement to primary analyses. In any case, it is worthwhile to attempt these two-stage procedures and the standard 1-stage Bonferroni test, while splitting FWER among them.

The asymptotic independence of the two-stage test statistics can be extended beyond the examples presented. Indeed, for any estimator of parameters in a generalized linear model (GLM), the score function can be written in a form of

$$X(Y - E[Y|X]) = 0.$$  

The proof in Section 3 applies immediately to the independence of estimators of MA and interaction. Thus the proposed two-stage procedure can be applied to any GLM outcome, e.g., Poisson counts. We show in Example 4 that approximation can be made for survival data in RCT with a rare event, so that the independence can be carried over to Cox partial likelihood. For survival data with a common event, however, the proposed two-stage procedures do not work in general. In future study, we intend to investigate the possibility of asymptotic independence using parametric survival analysis.

7. Acknowledgment

The authors of this manuscript were supported in part by U01 AI068615, U01 AI068617, U01 HG005152, R01 CA90998, P01 CA53996. The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221.

8. Appendix

8.1. Proof of Theorem 1

Proof. With mild regularity conditions, standard estimating equation theory imply that

$$\sqrt{n}(\hat{\theta}_k - \theta_k) \rightarrow_d \mathcal{N}(0, V_1),$$

$$\sqrt{n}(\hat{\theta}_j - \theta_j) \rightarrow_d \mathcal{N}(0, V_2),$$

where $V_1$ and $V_2$ are asymptotic variances which can be estimated by their respective empirical averages, $\hat{V}_1$ and $\hat{V}_2$. By the Law of Large Number, $\hat{V}_1$ and $\hat{V}_2$ are consistent estimators.

Since

$$\text{Cov}\left(\sqrt{n}(\hat{\theta}_k - \theta_k), \sqrt{n}(\hat{\theta}_j - \theta_j)\right) \rightarrow 0 \quad \text{as} \quad n \rightarrow \infty,$$

and

$$\frac{\sqrt{n}(\hat{\theta}_k - \theta_k)}{\sqrt{V_1}} - \frac{\sqrt{n}(\hat{\theta}_k - \theta_k)}{\sqrt{V_1}} = o_p(1),$$

$$\frac{\sqrt{n}(\hat{\theta}_j - \theta_j)}{\sqrt{V_2}} - \frac{\sqrt{n}(\hat{\theta}_j - \theta_j)}{\sqrt{V_2}} = o_p(1),$$

we derive that

$$\left(\frac{\sqrt{n}(\hat{\theta}_k - \theta_k)}{\sqrt{V_1}}, \frac{\sqrt{n}(\hat{\theta}_j - \theta_j)}{\sqrt{V_2}}\right) \rightarrow_d \mathcal{N}\left(\begin{bmatrix} 0 \\ 0 \end{bmatrix}, \begin{bmatrix} 1 & 0 \\ 0 & 1 \end{bmatrix}\right).$$
Since $T_k^0 = \hat{q}_k / \sqrt{V_1/n}$ and $T_j = \hat{q}_j / \sqrt{V_2/n}$, this implies $T_k^0$ and $T_j$ are asymptotically independent $\forall j, k$ under the global null hypothesis.

We now prove the main result. Observe that $m_0$ is a random variable taking values at $0, 1, \ldots, m$. Let $I_k$ denote a set of $k$ distinct integers from $\{1, \ldots, m\}$, that index the hypotheses passing the filter in the first stage. Let $J_k$ denote the collection (set) of all possible $I_k$. Note that

$$\lim_{n \to \infty} \Pr \{ \cup_{j \in J} (T_j^0 \in \Gamma_j^0 \cap T_j \in \Gamma_j) | H_{0j}, K_{0j} \}$$

$$= \lim_{n \to \infty} \sum_{k=1}^{m} \sum_{I_k \in J_k} \Pr \left[ \left( \bigcap_{j \in (J \cap I_k)} (T_j^0 \in \Gamma_j^0 | K_{0j}) \right) \cap \left( \bigcup_{j \in (J \cap I_k)} (T_j \in \Gamma_j | H_{0j}) \right) \right]$$

$$= \lim_{n \to \infty} \sum_{k=1}^{m} \sum_{I_k \in J_k} \Pr \{ \bigcap_{j \in (J \cap I_k)} (T_j^0 \in \Gamma_j^0 | K_{0j}) \} \Pr \{ \bigcup_{j \in (J \cap I_k)} (T_j \in \Gamma_j | H_{0j}) \}$$

$$\leq \lim_{n \to \infty} \sum_{k=1}^{m} \sum_{I_k \in J_k} \Pr \{ \bigcap_{j \in (J \cap I_k)} (T_j^0 \in \Gamma_j^0 | K_{0j}) \} \sum_{j \in (J \cap I_k)} \Pr \{ |T_j| \geq C_1 - \alpha/2k | H_{0j} \}$$

$$\leq \lim_{n \to \infty} \sum_{k=1}^{m} \sum_{I_k \in J_k} \Pr \{ \bigcap_{j \in (J \cap I_k)} (T_j^0 \in \Gamma_j^0 | K_{0j}) \} \alpha$$

$$\leq \alpha$$

The equality (10) holds by the asymptotic independence, the inequality (11) uses the Bonferroni inequality, (12) uses the fact that the size of the set $\{ j : j \in (J \cap I_k) \}$ is less than or equal to $k$, and (13) holds because

$$\sum_{k=0}^{m} \sum_{I_k \in J_k} \Pr \{ \bigcap_{j \in (J \cap I_k)} (T_j^0 \in \Gamma_j^0 | K_{0j}) \} = 1$$

if we denote by $I_0$ the empty set.

\[ \square \]

### 8.2. Proof of Theorem 2

**Proof.** The proof of asymptotic independence of $T_j^0$ and $T_j$ under the global null hypothesis is same as that in Theorem 1. Observe that

$$m_0 = \sum_{j=1}^{m} I(T_j^0 \in \Gamma_j^0 | K_j^0).$$

Unless $T_j^0$’s are independent, $\mathbb{E}[m_0]$ is generally not equal to $\alpha_0$. However if $\frac{m_0}{m} \to_p \alpha_0'$, we can prove the main result as followed:

$$\lim_{m \to \infty} \lim_{n \to \infty} \Pr \{ \cup_{j \in J} (T_j^0 \in \Gamma_j^0 \cap T_j \in \Gamma_j) | H_{0j}, K_{0j} \}$$

$$\leq \lim_{m \to \infty} \lim_{n \to \infty} \sum_{j=1}^{J} \Pr \{ (T_j^0 \in \Gamma_j^0 \cap T_j \in \Gamma_j) | H_{0j}, K_{0j} \}$$

$$= \lim_{m \to \infty} \lim_{n \to \infty} \sum_{j=1}^{J} \Pr (T_j^0 \in \Gamma_j^0) \Pr (T_j \in \Gamma_j | H_{0j})$$
Two-stage testing procedures via asymptotically independent statistics

\[
\lim_{m \to \infty} \left( \frac{1}{m} \sum_{j=1}^{J} \Pr \left( T_{j}^{0} \in \Gamma_{j}^{0} | K_{j}^{0} \right) \right) \frac{m \alpha}{m_{0}} \leq \frac{\alpha}{\alpha_{0}} \quad (16)
\]

The inequality (14) uses Bonferroni inequality, (15) uses the asymptotic independence of \( T_{j}^{0} \) and \( T_{j} \), (16) holds because

\[
\frac{1}{m} \sum_{j=1}^{J} \Pr \left( T_{j}^{0} \in \Gamma_{j}^{0} | H_{j}^{0} \right) \leq \alpha_{0},
\]

and by Slutsky’s Theorem

\[
\frac{m \alpha}{m_{0}} \to_{p} \frac{\alpha}{\alpha_{0}}.
\]

8.3. Proof of Lemma 1

**Proof.** (a) If the disease is rare, \( \Pr(Z|X, R = 1) \neq \Pr(Z|R = 1) \) implies \( \Pr(Z|X, Y = 1) \neq \Pr(Z|Y = 1) \), hence \( \Pr(Y|X, Z) \neq \Pr(Y|Z) \).

(b) If the disease is common and \( \Pr(Y|Z, X) = \Pr(Y|Z) \),

\[
\Pr(X|Y, Z) = \frac{\Pr(Y|X, Z)\Pr(X|Z)}{\Pr(Y|Z)} = \Pr(X|Z) = \Pr(X).
\]

This implies \( \Pr(X|Y) = \Pr(X) \). Now

\[
\Pr(Z, X|Y) = \frac{\Pr(Y|Z, X)\Pr(Z|X)}{\Pr(Y)} = \frac{\Pr(Y|Z)\Pr(Z|X)}{\Pr(Y)} = \Pr(Z|Y)\Pr(X) = \Pr(Z|Y)\Pr(X|Y).
\]

Hence \( Z \perp X|Y \). Since the sampling depends on \( Y \) only, this implies that \( Z \) and \( X \) are independent in the selected case-control samples, i.e.,

\[
\Pr(Z|X, R = 1) = \Pr(Z|R = 1).
\]

Note that if \( \Pr(Y|X, Z) = \Pr(Y|X) \), the same argument leads to the conclusion that \( Z \) and \( X \) are independent in the selected case-control sample. So we need the condition \( \Pr(Y|X, Z) \neq \Pr(Y|X) \) to ensure that it is possible to observe \( \Pr(Z|X, R = 1) \neq \Pr(Z|R = 1) \).

References


Two-stage testing procedures via asymptotically independent statistics


